Pioneering new treatments
for Osteoarthritis.

Who We Are

We are a highly innovative life sciences company based in the West of Ireland. 
At Relevium Medical, our core focus is the development of novel, hydrogel-based therapeutics for first-in-class pain relief. Relevium Medical combines expertise in chemistry, engineering, and cutting edge medical science to pioneer radical solutions meeting the needs of pain patients. The patented Hydrobloc-01 bio-therapeutic has been developed by the company to specifically treat patients with pain from knee osteoarthritis. This award-winning technology has already resulted in €1.35 million in direct funding from National and European sources to facilitate development.
SFI logo

Science Foundation Ireland
Winner

EIT logo

EIT Headstart
Winner

Our Mission

Relevium Medical’s mission is to improve the quality of life for people living with osteoarthritis by developing highly innovative treatments that provide superior pain relief and keep people active for longer.

Osteoarthritis

Osteoarthritis pain is routinely described as Europe’s largest hidden disability, affecting over 80 million European and US citizens. The most common form of OA affects the knee joint, representing 40% of cases (32 million).

1 M
European & US Citizens affected

Commonly Affected Joints:

Our Current Target

Asset 3@2x

Knee

Asset 1@2x

Cervical
Spine

Shoulder@300x

Shoulder

Hip

Knee Osteoarthritis

Knee Pain 2

Knee osteoarthritis (Knee OA) is a painful, debilitating, and progressive condition without long-lasting, effective treatment options. In Knee OA progressive degradation and destruction of the bone and cartilage in the joint results in pain, stiffness, and loss of mobility. 

1 M
eUROPEANS
1 M
Americans

Affected

1 th

Leading cause of disability worldwide 

$ 1 k

Lifetime costs per patient

1 %

of patients are unsatisfied with current treatments

Our Product

Hydrobloc-01 is a patent protected novel bio-therapeutic for the treatment of Knee Osteoarthritis. It provides long lasting and effective pain relief, which is superior to competitor products.

Hydrobloc-01

Development to Date

IP Patent Filed

Pricing Strategy

Feasibility Testing

Formulation

Preclinical Testing

Our Team

Dr. Alison Liddy

CEO & Founder

  • PhD in Biochemical Engineering.
  • 18 years of industry experience.
  • Raised over €10 million in funding to date.

Mr. Damien Kelly

CFO

  • Former CFO Mylan Pharmaceuticals
  • 25 years of commercial experience.
  • Successfully grown businesses to valuations of over €1 Billion.

Dr. Barry McDermott

CTO

  • PhD in Biomedical Engineering.
  • Uniquely qualified as a veterinary surgeon, research pharmacist and engineer.
  • 20 years of Pharmaceutical and MedTech experience.

Get In Touch

Leave us a message

7 Tor Buí, Cappagh Road, Knocknacarra, Galway, H91 PRC6

info@relevium-medical.com

Follow Us

©Relevium Medical 2020 All Rights Reserved

Supported By

Scroll Up